Rigvir is a pioneering company in the field of oncolytic virotherapy, specifically known for its product ECHO-7, which is derived from the ECHO-7 virus. This virus has been recognized as the first oncolytic virus to be registered as a medicine, achieving this milestone in Latvia in 2004. Rigvir has undergone extensive preclinical and clinical trials, demonstrating its effectiveness and safety in treating various forms of melanoma, including stage IIA and IIIB. The company has established exclusive licensing agreements for the manufacturing and use of the Rigvir virus, allowing it to expand its reach into scientific and industrial applications, as well as into non-medical sectors for cancer prevention.

The Rigvir Group is committed to advancing cancer treatment through innovative biotechnological approaches. Their research focuses on the immunomodulatory effects of the ECHO-7 virus, which has shown promise in enhancing the immune response against tumors. Rigvir's ongoing studies and clinical trials aim to explore its efficacy in combination with other therapies, such as checkpoint inhibitors, to improve patient outcomes. The company is also expanding its global footprint through partnerships, including a recent collaboration with a Chinese biotech firm to develop and commercialize ECHO-7 in the Chinese market, further solidifying its position as a leader in oncolytic virotherapy.

Latvia

Rigvir Group is a biotech company that has launched the food supplement Rigvir SE on the market. The company has also concluded a deal with Chinese biotech company Sinorda Biomedicine on the development and commercialization of ECHO-7 oncolytic virotherapy cancer. Rigvir Holding is the manufacturer of a commercialized ECHO-7 virus that has been clinically used for cutaneous melanoma with trademark RIGVIR®.

Rigvir

Company Details